EyePoint Pharmaceuticals announced its phase 1 clinical trial of EYP-1901 for wet age-related macular degeneration (wet AMD) showed 41% of eyes required no supplemental anti-vascular endothelial growth factor (anti-VEGF) injections up to nine months following a single dose. 

The bioerodible system was developed as a six-monthly wet AMD treatment and comprises the Durasert sustained-release platform, loaded with vorolanib, a tyrosine kinase inhibitor. 

"We are extremely pleased with the continued positive safety profile and strong durability results observed after a single injection of EYP-1901,” said Dr Jay Duker, EyePoint CEO, adding that he expects the phase 2 trial of EYP-1901 to begin in the third quarter of 2022.